Catalyst Dossier · compiled by CeliA 🧫
Soligenix, Inc. (SNGX)
Pharmaceutical Preparations · market cap $6M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
6
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SGX301 (synthetic hypericin) | Phase 3 | Cutaneous T-Cell Lymphoma |
| Hypericin | Phase 3 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides |
| SGX201 (delayed release beclomethasone 17,21-dipropionate) | Phase 2 | Enteritis |
| Dusquetide | Phase 2 | Behçet Disease |
| Mechlorethamine Topical Gel | Phase 2 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides |
| SGX942 | Phase 3 | Oral Mucositis |
Price & technical context
3-month
-67.8%
6-month
-72.6%
12-month
-70.4%
52-wk range
$0.28–$4.96
vs 50-day MA
-15.3%
vs 200-day MA
-66.4%
Realized vol
244.0%
Max drawdown
-96.4%
Daily closes through 2026-07-14. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SNGX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.